Last edition
News about "Dyne Therapeutics"
Dyne Therapeutics' Duchenne Muscular Dystrophy Therapy Receives FDA Priority Review
FDA accepts Biologics License Application for investigational exon 51-skipping therapy z-rostudirsen, with a regulatory decision expected by January 2027.
Dyne Therapeutics | 22/07/2026 | By News Bureau
Dyne Therapeutics Reports Positive Results from Z-Rostudirsen DMD Study
Dyne Therapeutics reported new 24-month data from the DELIVER trial showing Z-rostudirsen improved cardiopulmonary function in patients with Duchenne Muscular Dystrophy (DMD), building on earlier findings of sustained functional benefits across multiple clinical measures.
Dyne Therapeutics | 09/03/2026 | By News Bureau | 164
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy